Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
Earnings Data
Report Date
Apr 24, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
3.01Last Year’s EPS
2.46Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed broad operational strength: record sales, multiple high‑growth franchises (notably SKYRIZI, RINVOQ, and neuroscience brands), significant R&D and BD investments, and an optimistic 2026 financial outlook (≈9.5% revenue growth, EPS guidance and margin expansion). Headwinds were clearly disclosed — substantial HUMIRA erosion, declines in IMBRUVICA and parts of aesthetics, acquired IPR&D charges compressing near‑term margins, and modest pricing pressure on key immunology assets — but management articulated clear mitigation levers (strong portfolio growth, new approvals, pipeline catalysts, BD additions, and a large free cash flow profile). Overall, positive execution and outlook outweigh the listed challenges.Company Guidance
Record Revenue and EPS Outperformance
Full-year adjusted EPS of $10, $0.54 above initial guidance midpoint; total net revenues (ex-IPR&D) $61.2B, beating initial guidance by >$2B; sales growth 8.6% led to an all-time high, exceeding prior peak by >$3B despite nearly $16B of U.S. HUMIRA erosion since LOE.
Robust Immunology Momentum (SKYRIZI & RINVOQ)
Q4 immunology revenues ~ $8.6B. SKYRIZI Q4 sales $5B (operational growth 31.9%); RINVOQ Q4 sales ~$2.4B (operational growth 28.6%). Combined FY SKYRIZI + RINVOQ ≈ $25.9B, up ~ $8B YoY; SKYRIZI IBD global sales ~$6.4B in 2025 (more than double prior year); SKYRIZI US biologic psoriasis prescription share >45% and frontline in-play capture ~75% in IBD.
Neuroscience Outperformance and Parkinson's Launch
Full-year neuroscience revenues >$10.7B, up ~$1.8B YoY; Q4 neuroscience +17.3% operational. Key brands: Vraylar $1B, Botox Therapeutic $990M, UBRELVY $339M, QULYPTA $288M. Violet (Parkinson's) Q4 sales $183M, +33% sequential; company now expects Violet to reach blockbuster status in 2026.
Pipeline Progress and R&D Investment
Adjusted R&D expense increased by nearly $1B in 2025, fully funding 90 clinical programs. New approvals include RINVOQ (GCA), EMERALIS (nonsquamous NSCLC), and Epkinle (2L follicular lymphoma). >$5B invested in business development adding in‑vivo CAR T, next‑gen psychedelics, trispecific antibodies, long‑acting amylin analog (ABBV‑295), siRNA platform and a PD‑1/VEGF bispecific from Remagen.
2026 Financial Guidance and Margin Expansion
2026 guidance: total net revenues ≈ $67B (growth 9.5%), adjusted EPS $14.37–$14.57. Forecasted adjusted gross margin >84%, adjusted operating margin ~48.5% (meaningful expansion vs 2025). Free cash flow expected ~$18.5B in 2026 to support dividends and BD.
Strategic U.S. Agreement and Capital Commitment
Voluntary three‑year agreement with the U.S. government to expand patient access (low Medicaid prices, direct-to-patient cash pay options) and commit $100B in U.S. R&D and capital investments over the next decade, aligning affordability and innovation objectives.
ABBV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ABBV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $225.66 | $217.11 | -3.79% |
Oct 31, 2025 | $226.38 | $216.30 | -4.45% |
Jul 31, 2025 | $186.45 | $186.17 | -0.15% |
Apr 25, 2025 | $176.13 | $181.68 | +3.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does AbbVie (ABBV) report earnings?
AbbVie (ABBV) is schdueled to report earning on Apr 24, 2026, Before Open (Confirmed).
What is AbbVie (ABBV) earnings time?
AbbVie (ABBV) earnings time is at Apr 24, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABBV EPS forecast?
ABBV EPS forecast for the fiscal quarter 2026 (Q1) is 3.01.
